Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Bought by Blair William & Co. IL

Blair William & Co. IL raised its holdings in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) by 29.2% during the second quarter, HoldingsChannel reports. The firm owned 88,466 shares of the company’s stock after buying an additional 20,000 shares during the period. Blair William & Co. IL’s holdings in Vistagen Therapeutics were worth $308,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. American Century Companies Inc. increased its stake in Vistagen Therapeutics by 49.1% in the second quarter. American Century Companies Inc. now owns 30,315 shares of the company’s stock valued at $105,000 after purchasing an additional 9,984 shares during the period. Acadian Asset Management LLC acquired a new position in Vistagen Therapeutics in the first quarter valued at $169,000. AdvisorShares Investments LLC acquired a new position in Vistagen Therapeutics in the fourth quarter valued at $279,000. ADAR1 Capital Management LLC acquired a new position in Vistagen Therapeutics in the fourth quarter valued at $1,262,000. Finally, Armistice Capital LLC acquired a new position in shares of Vistagen Therapeutics during the fourth quarter worth about $2,457,000. 78.39% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, William Blair upgraded shares of Vistagen Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th.

Vistagen Therapeutics Stock Down 2.0 %

Shares of Vistagen Therapeutics stock opened at $3.00 on Friday. Vistagen Therapeutics, Inc. has a 52-week low of $2.45 and a 52-week high of $5.86. The company’s 50-day simple moving average is $3.37 and its 200-day simple moving average is $3.92. The firm has a market cap of $81.08 million, a price-to-earnings ratio of -1.45 and a beta of 0.80.

Vistagen Therapeutics (NASDAQ:VTGN) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.06. The business had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.30 million. Vistagen Therapeutics had a negative net margin of 3,421.85% and a negative return on equity of 35.12%. During the same period in the previous year, the business posted ($0.94) earnings per share. Equities research analysts anticipate that Vistagen Therapeutics, Inc. will post -1.79 EPS for the current year.

Vistagen Therapeutics Company Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.